MARK BLIZZARD: Open Payments
NPI 1043945041 · GOLDSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,925 in 112 payments from 26 companies in 2025. Trend: 2023 $1,816 · 2024 $1,815 · 2025 $1,925
Food & beverage: $1,925
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $248 |
| Astellas Pharma US Inc | 9 | $164 |
| Novo Nordisk Inc | 10 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $142 |
| Aimmune Therapeutics, Inc. | 6 | $132 |
| Corcept Therapeutics | 6 | $120 |
| Ardelyx, Inc. | 7 | $119 |
| ABBVIE INC. | 5 | $98 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 4 | $80 |
Products named: BREZTRI, Veozah, XIFAXAN, ZENPEP, Korlym, IBSRELA, REXULTI, Kerendia.
Industry payments across NC — which companies pay providers there.
